A bivalent cyclic RGD–siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts

The vascular endothelial growth factor receptor 2 (VEGFR2) is considered to be a pivotal target for anti-tumor therapy against angiogenesis of non-small cell lung cancer (NSCLC). However, effective and low-toxicity targeted therapies to inhibit VEGFR2 are still lacking. Here, biRGD–siVEGFR2 conjugat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Lumin, Cen, Bohong, Li, Guoxian, Wei, Yuanyi, Wang, Zhen, Huang, Wen, He, Shuai, Yuan, Yawei, Ji, Aimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274511/
https://www.ncbi.nlm.nih.gov/pubmed/34236267
http://dx.doi.org/10.1080/10717544.2021.1937381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274511/
https://www.ncbi.nlm.nih.gov/pubmed/34236267
http://dx.doi.org/10.1080/10717544.2021.1937381

Ejemplares similares